AI-generated analysis. Always verify with the original filing.
PepGen Inc. announced fourth quarter and year-end 2025 financial results, reporting $148.5 million in cash sufficient into 2H 2027, reduced R&D expenses, and narrower net losses. The FDA placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 trial related to preclinical studies, while FREEDOM2 5 mg/kg data is expected in Q1 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 4, 2026, PepGen Inc. (the "Company") announced its financial results for the year ended December 31, 202
Other Events. On March 4, 2026, the Company announced that it received a partial clinical hold notice from the U.S. Food and Drug Administration on the FREEDOM2
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by PepGen Inc. on March 4, 2026 titled "PepGen Reports Four
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $13.90 | |
| Research and Development Expenses | $71.00 | |
| General and Administrative Expenses | $5.90 | |
| General and Administrative Expenses | $22.60 | |
| Net Loss | $18.30 | |
| Basic and Diluted Net Loss per Share | $-0.27 | |
| Net Loss | $89.70 | |
| Basic and Diluted Net Loss per Share | $-2.12 |
Joseph Vittiglio, Esq.
Effective: 2025-12